PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
6.22%
Cash & equivalents growing 6.22% while TRAW's declined -8.97%. Peter Lynch would see this as a sign of superior liquidity management.
-100.00%
Short-term investments yoy growth ≥ 1.5x TRAW's -24.99%. David Dodd would see a more robust near-cash position, but confirm efficient allocation.
6.22%
Below half of TRAW's -15.38%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other current assets growth < half of TRAW's 15.81%. David Dodd sees a leaner approach to short-term items.
13.80%
Below half of TRAW's -14.72%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
2.11%
Below half TRAW's -11.02%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.11%
Below half of TRAW's -9.04%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
13.78%
Below half of TRAW's -14.68%. Michael Burry sees a potential red flag for stagnation or capital shortage.
62.36%
Less than half of TRAW's -11.00%. David Dodd sees a more disciplined AP approach or lower volume.
-40.14%
Higher Short-Term Debt Growth compared to TRAW's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
133.46%
Below half of TRAW's -42.26%. Michael Burry suspects a big gap in pre-sales traction.
184.58%
1.25-1.5x TRAW's 141.13%. Martin Whitman sees a potentially higher near-term liability load.
173.41%
Above 1.5x TRAW's 11.78%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
173.41%
Above 1.5x TRAW's 4.54%. Michael Burry sees a potential leverage warning sign.
4.06%
Above 1.5x TRAW's 0.93%. Michael Burry suspects heavy new equity expansion or dilution.
-25.11%
≥ 1.5x TRAW's -8.09%. David Dodd sees higher yoy retained profits than competitor.
-90.06%
Similar yoy to TRAW's -100.00%. Walter Schloss sees parallel comprehensive income changes.
-100.00%
Higher Other Stockholders' Equity Items Growth compared to TRAW's zero value, indicating worse performance.
-763.59%
≥ 1.5x TRAW's -20.52%. David Dodd sees stronger capital base growth than competitor.
13.78%
Below half TRAW's -14.68%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
-100.00%
≥ 1.5x TRAW's -24.99%. David Dodd sees far stronger investment expansions than competitor.
-40.14%
Higher Total Debt Growth compared to TRAW's zero value, indicating worse performance.
-7.59%
Less than half of TRAW's 8.97%. David Dodd sees better deleveraging or stronger cash buildup than competitor.